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Abstract
Background: Anthracyclines and taxanes are commonly used in the treatment of breast cancer.
However, tumor resistance to these drugs often develops, possibly due to overexpression of drug
transporters. It remains unclear whether drug resistance in vitro occurs at clinically relevant doses
of chemotherapy drugs and whether both the onset and magnitude of drug resistance can be
temporally and causally correlated with the enhanced expression and activity of specific drug
transporters. To address these issues, MCF-7 cells were selected for survival in increasing
concentrations of doxorubicin (MCF-7DOX-2), epirubicin (MCF-7EPI), paclitaxel (MCF-7TAX-2), or
docetaxel (MCF-7TXT). During selection cells were assessed for drug sensitivity, drug uptake, and
the expression of various drug transporters.
Results: In all cases, resistance was only achieved when selection reached a specific threshold
dose, which was well within the clinical range. A reduction in drug uptake was temporally
correlated with the acquisition of drug resistance for all cell lines, but further increases in drug
resistance at doses above threshold were unrelated to changes in cellular drug uptake. Elevated
expression of one or more drug transporters was seen at or above the threshold dose, but the
identity, number, and temporal pattern of drug transporter induction varied with the drug used as
selection agent. The pan drug transporter inhibitor cyclosporin A was able to partially or
completely restore drug accumulation in the drug-resistant cell lines, but had only partial to no
effect on drug sensitivity. The inability of cyclosporin A to restore drug sensitivity suggests the
presence of additional mechanisms of drug resistance.
Conclusion: This study indicates that drug resistance is achieved in breast tumour cells only upon
exposure to concentrations of drug at or above a specific selection dose. While changes in drug
accumulation and the expression of drug transporters does occur at the threshold dose, the
magnitude of resistance cannot be attributed solely to changes in drug accumulation or the activity
of drug transporters. The identities of these additional drug-transporter-independent mechanisms
are discussed, including their likely clinical relevance.
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Background
While anthracyclines and taxanes are highly effective
drugs used in the treatment of breast and other cancers,
tumour drug resistance mechanisms limit their clinical
effectiveness. Tumours can either be intrinsically resistant
to chemotherapy agents, or acquire resistance upon expo-
sure to a previous round of chemotherapy [1]. Drug resist-
ance, whether intrinsic or acquired, is believed to cause
treatment failure in over 90% of patients with metastatic
cancer [2]. Thus, it is critical that clinically relevant mech-
anisms for drug resistance be elucidated in order to iden-
tify approaches to circumvent drug resistance. A wide
variety of proteins or protein mutations have been found
to play a role in drug resistance in vitro, but their relevance
clinically remains to be established [2-4].
To date, six drug transporters have been shown to play a
role in multidrug resistance in tumour cells in vitro. These
include ABCB1 (P-glycoprotein), ABCC1 (MRP1), ABCC2
(MRP2), ABCC4 (MRP4), ABCG2 (BCRP), and the lung
resistance protein (LRP). Of these, three are overexpressed
in the large majority of tumour cell lines that have been
successfully selected for resistance to anthracyclines and
taxanes. These include ABCB1, ABCC1, and ABCG2, and
all play a role in reducing the ability of tumour cells to
accumulate specific chemotherapy drugs [5,6]. Although
these transporters are unique in their sequences, there is
some overlap in the drugs that can be transported by each
protein. ABCC1 confers resistance to doxorubicin, dauno-
rubicin, vincristine, etoposide, epirubicin, chlorambucil,
methotrexate, melphalan and paclitaxel [5,7-9]. ABCC2
has been shown to be associated with resistance to doxo-
rubicin, etoposide, methotrexate, irinotecan (SN-38), vin-
cristine, vinblastine, camptothecin (CPT-11) [9],
paclitaxel, docetaxel, etoposide, mitoxantrone [10] and
cisplatin [11]. ABCC4 is believed to confer resistance to
the camptothecins (SN-38, rubitecan, irinotecan), cyclo-
phosphamide [12], topotecan [13], methotrexate, and
nucleoside analogues [14]. Numerous studies have been
conducted on ABCB1 and its ability to transport chemo-
therapy drugs. It has been shown to directly transport vin-
blastine, paclitaxel, docetaxel, daunorubicin,
doxorubicin, epirubicin, etoposide, teniposide, and
mitoxantrone [9,15-18]. The final ABC transporter
(ABCG2) confers resistance to mitoxantrone, doxoru-
bicin, epirubicin, daunorubicin, vinca alkaloids, paclit-
axel, cisplatin, etoposide, teniposide, irinotecan,
topotecan, and camptothecin [9,19-24]. Although not an
ABC transporter, lung resistance-related protein (LRP) is a
human major vault protein whose expression appears to
correlate with resistance to doxorubicin, mitoxantrone,
methotrexate, etoposide, vincristine, and cisplatin
[reviewed in [25]]. While the exact cellular function of the
major vault proteins (MVP) remains to be elucidated, the
majority of these proteins have been shown to interact
with cytoskeletal elements or within the nucleus—in par-
ticular nucleoli, the nuclear membrane and/or the nuclear
pore complex [25-27]. Elevated levels of MVPs have been
observed in some drug-resistant cell lines. While there is
little direct evidence that the proteins can directly trans-
port chemotherapy drugs, it has been shown that overex-
pression of LRP alters the subcellular distribution of
doxorubicin, such that the drug localizes to cytoplasmic
organelles rather than to DNA within the nucleus [28].
Despite the overwhelming evidence that drug transporters
can confer resistance to a variety of chemotherapy agents
in tumour cells in vitro, attempts to use their expression as
definitive biomarkers for the identification of drug resist-
ant tumours have met with mixed success [29-32]. In
addition, administration of drug transporter inhibitors
(in particular for ABCB1) to prevent or reverse drug resist-
ance in cancer patients has largely been unsuccessful, in
part due to the toxicity of these compounds [33,34].
Given these findings, it is likely that additional mecha-
nisms may play an equal or much greater role in clinical
resistance to chemotherapy drugs. Inhibition of these tar-
gets may prove more fruitful in combating drug resistance
in patients. To rigorously assess the temporal and causal
relationships between the acquisition of drug resistance
and the induction of drug transporters and drug accumu-
lation defects in vitro, we selected MCF-7 breast tumour
cells for survival in increasing concentrations of paclitaxel,
docetaxel, doxorubicin, or epirubicin. We then examined
cells during selection for their expression of various drug
transporters, their sensitivity to various chemotherapy
agents, their ability to uptake drugs, and their sensitivity
to a pan-ABC drug transporter inhibitor. Our findings sug-
gest that changes in cellular drug accumulation do tempo-
rally correlate with the acquisition of drug resistance at
clinically relevant drug doses. However, the onset of drug
resistance is not always correlated with the induction of
specific drug transporters. Moreover, inhibition of drug
transporter function and/or restoration of drug accumula-
tion has only limited to no ability to restore sensitivity to
chemotherapy agents. Additional mechanisms which are
temporally and functionally correlated with the acquisi-
tion of drug resistance are discussed.
Methods
Selection of MCF-7 Cells for Resistance to Various 
Chemotherapy Drugs
MCF-7 cells were selected for progressive resistance to
doxorubicin or paclitaxel as previously described [35]
except that an aliquot of cells was stored before each esca-
lation in drug dose. Selection began at a drug dose (dose
1) that was 1000-fold less than the concentration at which
50% of parental MCF-7 cells are killed (the IC50). The
dose was then increased 1.5- or 3-fold until the maximally
tolerated dose was achieved. Similar selections were per-BMC Cancer 2008, 8:318 http://www.biomedcentral.com/1471-2407/8/318
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formed in an identical manner to obtain cells exhibiting
progressive resistance to epirubicin or docetaxel. Table 1
depicts the drug concentrations (doses) to which the cells
were exposed. The panel of cell lines selected for progres-
sive resistance to paclitaxel, docetaxel, doxorubicin, or
epirubicin were referred to as MCF-7TAX-2, MCF-7TXT, MCF-
7DOX-2, and MCF-7EPI cells, respectively, and the dose to
which cells were selected noted. For example, MCF-7DOX-
2cells selected to dose 9 refers to MCF-7 cells that were
exposed to step-wise increases in the concentration of
doxorubicin until the selection dose reached 29.1 nM
doxorubicin (see Table 1). MCF-7TAX-2 and MCF-7DOX-2
were given the "-2" nomenclature to distinguish these
cells from paclitaxel- and doxorubicin-resistant cell lines
previously isolated by our laboratory (MCF-7TAX  and
MCF-7DOX, respectively) [35-37]. During each selection
for drug resistance, an identical "selection" was performed
in the absence of drug ("co-cultured control" or MCF-7CC
cells) in order to account for any changes in drug sensitiv-
ity or other cell phenotypes associated with long-term
propagation in culture.
Measurement of Cellular Drug Sensitivity
Drug sensitivity for cells at various selection doses was
measured using a clonogenic assay as described previ-
ously [35]. The effect of 5 μM cyclosporin A on drug sen-
sitivity was also determined using a clonogenic assay,
except that only cells selected to doses 9 or 12 were used
and the agent was added 1 hour prior to the addition of
chemotherapy drugs. The concentration at which 50% of
cells are killed (the IC50 value) was computed for both
MCF-7CC cells and cells selected for resistance at specific
selection doses. Resistance factors for cells at each selec-
tion dose were then computed by dividing the IC50 value
for the drug-selected cells by the IC50 value for MCF-7CC
cells at that dose.
Measurement of 3H-Paclitaxel Uptake Into Cells
Radiolabelled paclitaxel uptake into cells was monitored
as described previously [35], except that some cells were
pre-treated with 5 μM cyclosporin A rather than 2 μM val-
spodar. All values presented were an average of 3 trials,
and the percent uptake expressed relative to uptake into
MCF-7CC cells at 24 hours.
Measurement of Doxorubicin and Epirubicin Uptake Into 
Cells
Doxorubicin uptake into cells was monitored as described
previously [35] with the exception that 4.0 × 105 cells were
used in the assay, and pre-treatment of some cells was
with 5 μM cyclosporin A rather than 2 μM valspodar. All
values presented were an average of 3 trials, and the per-
cent uptake expressed relative to uptake into MCF-7CC
cells at 16 hours. Epirubicin uptake was performed in an
identical manner to that of doxorubicin uptake.
Quantification of Drug Transporter Transcripts
Quantification of cellular transcripts for various drug
transporters was conducted by "real time" quantitative
reverse transcription PCR (Q-PCR) using RNA isolated
from cells at various selection doses and gene-specific
primers as described previously [38]. The primers used
were: S28: 5'-TCCATCATCCGCAATGTAAAAG-3' and 5'-
GCTTCTCGCTCTGACTCCAAA-3'; ABCB1: 5'-GCAGCT-
GGAAGACAAATACACAA-3' and 5'-CCCAACATCGT-
GCACA- TCA-3'; ABCC1: 5'-GCTGGAGTGTGTGGGCAAC
T-3' and 5'-CTGAGGCTGTGCCT-GGAGAT-3'; ABCC2: 5'-
TCCTTGCGCAGCTGGATTACAT-3' and 5'-TCGCTGAAG
TGA-GAGTAGATTG-3'; ABCC4: 5'-CCCCTGAAGGCT-
TCTTGTTAGA-3' and 5'-GGGTAC-ACACTCCCTACTA-
CAATGTC-3'; ABCG2: 5'AACCTGGTCTCAACGCCATC-3'
and 5'-GTCGCGGTGCTCCATTTATC-3'; LRP/MVP: 5'-
CAGCTGGCCATCGAGATCA-3' and 5'-CATCCCGA-
GACACAGGGTTG-3'.
cDNA Microarray Analysis of Wildtype and Drug-Resistant 
Cell Lines
cDNA microarray analyses were performed using RNA iso-
lated from MCF-7CC, MCF-7DOX-2, MCF-7EPI, MCF-7TAX-2,
and MCF-7TXT cells (selected to dose level 12) as described
previously [37]. Human microarrays (1.7v8) were from
the University Health Network (Toronto, ON). These
arrays were used to assess the level of expression of over
1700 unique gene sequences. After scanning, the microar-
rays were analysed and Significance Analysis of Microar-
rays (SAM) graphs generated using the Multiexperiment
Viewer v4 software, which is part of the TM4 software
Table 1: Concentrations of chemotherapy drugs used at each 
selection dose
Dose Doxorubicin Epirubicin Paclitaxel Docetaxel
IC50 8.91 nM 4.79 nM 0.56 nM 0.51 nM
1 8.91 pM 4.79 pM 0.56 pM 0.51 pM
2 26.7 pM 14.4 pM 1.67 pM 1.52 pM
3 80.1 pM 43.2 pM 5.01 pM 4.56 pM
4 240 pM 130 pM 15.0 pM 13.7 pM
5 720 pM 390 pM 45.0 pM 41.1 pM
6 2.16 nM 1.17 nM 135 pM 123 pM
7 6.48 nM 3.51 nM 405 pM 369 pM
8 19.4 nM 10.5 nM 1.22 nM 1.11 nM
9 29.1 nM 31.5 nM 3.66 nM 3.33 nM
10 43.6 nM 94.5 nM 11.0 nM 5.00 nM
11 65.4 nM 284 nM 33.0 nM 15.0 nM
12 98.1 nM* 852 nM 99.0 nM 45.0 nM*
MCF-7 breast tumour cells were exposed to progressively higher 
concentrations (doses) of chemotherapy drugs, beginning at a dose 
equivalent to 1/1000th of the concentration required to kill or inhibit 
the growth of 50% of wild-type MCF-7 cells (the IC50). The symbol * 
denotes the highest concentration of drug at which the cells could 
survive (the maximally tolerated dose).BMC Cancer 2008, 8:318 http://www.biomedcentral.com/1471-2407/8/318
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suite available freely from the J. Craig Venter Institute
http://www.tm4.org/index.html.
Immunoprecipitation and Immunoblotting of ABCB1 and 
ABCC1
Protein extracts from MCF-7CC, MCF-7DOX-2, MCF-7EPI,
MCF-7TAX-2, and MCF-7TXT cells (selected to dose level 12)
were prepared by washing adherent cells in PBS and scrap-
ing the cells in a lysis buffer containing 20 mM Tris pH
7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton
X-100, and 1 Complete™ Protease Inhibitor Tablet for
every 50 ml of prepared buffer. After homogenization and
clarification of the lysate, 300 μg of total protein from
each lysate was incubated with 5 μl of either an ABCB1-
specific antibody (C219 – Cedarlane Laboratories, Burl-
ington, ON) or ABCC1-specific antibody (QCRL-1, Santa
Cruz Biotechnology Inc, Santa Cruz, CA) for 1 hour on
ice. After the incubation with the antibody, 25 μl of pro-
tein A/G sepharose was added and allowed to incubate
overnight at 4°C on a rocker. The following day, the tubes
were centrifuged for 5 minutes at 16000 × g and the result-
ing pellet was washed 4 times with lysis buffer. The sepha-
rose pellet was then resuspended in equal volumes of lysis
buffer and gel loading buffer, and the entire sample was
loaded onto an 8% SDS-polyacrylamide gel. Western blot-
ting experiments were then performed using standard
procedures. Membranes, after blocking, were incubated
overnight at 4°C with a 1:100 dilution of either primary
antibody, followed by the appropriate secondary anti-
body for 1 hour at room temperature.
Statistical Analyses
To determine if differences in paclitaxel, doxorubicin and
epirubicin uptake were statistically significant, a two fac-
tor ANOVA (with replication) was performed with a
Tukey's post hoc test. To determine if differences in gene
levels seen in the four different cell lines using Q-PCR
were statistically significant, the non-parametric Kruskal-
Wallis test was used.
Results
Assessment of Isogeneity Between MCF-7CC Cells and Its 
Drug-Resistant Variants
cDNA microarray analyses were performed on RNA
extracted from MCF-7CC, MCF-7DOX-2, MCF-7EPI, MCF-
7TAX-2, and MCF-7TXT cells (selected to dose level 12). The
SAM plots from such analyses (Figure 1) indicated that the
expression levels of the vast majority of genes in MCF-
7DOX-2, MCF-7EPI, MCF-7TAX-2, and MCF-7TXT cells were
very similar to MCF-7CC cells. This strongly suggests that
the cell lines are isogenic and that the drug-resistant deriv-
ative cell lines do not stem from rare variants or contami-
nating cells within the population. A number of genes
were upregulated or downregulated in the drug-resistant
cell lines relative to MCF-7CC cells (red and green spots on
SAM plots, respectively), but these were few in number
and likely relate to changes in gene expression associated
with the acquisition of drug resistance. MCF-7DOX-2 cells
exhibited the greatest changes in gene expression, while
MCF-7EPI cells showed the fewest changes. The microarray
data thus suggest that a variety of genes and their protein
products contribute to acquired drug resistance in breast
tumour cells.
Tolerance of MCF-7 Cells to Increasing Concentrations of 
Anthracyclines and Taxanes
Selection of cells in the presence of increasing concentra-
tions of doxorubicin, epirubicin, paclitaxel, or docetaxel
(MCF-7DOX-2, MCF-7EPI, MCF-7TAX-2 and MCF-7TXT cells,
respectively) was carried out simultaneously under identi-
cal culture conditions (see Materials and Methods). Begin-
ning at a concentration 1000-fold less than the
empirically-derived IC50 for each drug (dose 1), MCF-7TAX-
2 and MCF-7EPI cells survived 3-fold increases in drug dose
until the maximally tolerated dose was reached or selec-
tion was stopped. In contrast, MCF-7DOX-2 cells survived
only 1.5-fold increases in the doxorubicin selection dose
at or above dose 9 until the maximally tolerated dose
(98.1 nM) was reached (dose 12). MCF-7TXT cells were
unable to survive a 3-fold increase at dose 10, but were
able to survive subsequent 3-fold increases in the selec-
tion dose until the maximally tolerated dose (45 nM) was
reached (dose 12).
A Threshold Drug Concentration is Required for 
Acquisition of Resistance to Anthracyclines and Taxanes
Clonogenic assays were conducted to measure the sensi-
tivity of cells to doxorubicin, epirubicin, paclitaxel, or
docetaxel during selection in increasing concentrations of
each of the 4 chemotherapy drugs. The IC50 values for
each drug in each of the cell lines (including MCF-7CC
cells) at the various selection doses were then determined
and resistance factors computed as described in Materials
and Methods. No resistance to the 4 chemotherapy agents
was seen in any of the cell lines when the selection dose
was less than or equal to dose 7 (data not shown). Even at
dose 8 (which is closest to the IC50 value of MCF-7 cells for
each drug), little to no drug resistance was observed
(Table 2). However, when dose 9 was reached, resistance
to the selection agent and to a drug of similar structure
were very apparent (Table 2). Interestingly, this suggests
that the drug used during selection must reach a specific
threshold concentration before any degree of drug resist-
ance is achieved. As shown in Table 2, this threshold dose
was typically dose 9 (which exceeds the IC50 for MCF-7
cells by between 3.3- and 6.6-fold).
MCF-7DOX-2 cells selected to dose 9 exhibited a 2.5-fold
resistance to doxorubicin and a 2.9-fold cross resistance to
epirubicin. Resistance factors increased as the selectionBMC Cancer 2008, 8:318 http://www.biomedcentral.com/1471-2407/8/318
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dose increased, resulting in a 28-fold resistance to doxoru-
bicin and a 4.8-fold cross-resistance to epirubicin for
MCF-7DOX-2 cells at dose 12. In contrast to the doxoru-
bicin-resistant cells, MCF-7EPI cells showed larger resist-
ances at dose 9 (94-fold resistance to epirubicin and 39-
fold resistance to doxorubicin). These resistances
increased with increasing selection dose, culminating
with 203-fold resistance to doxorubicin and 815-fold
resistance to epirubicin at dose 12.
MCF-7 cells exposed to increasing concentrations of tax-
anes also developed resistance to these agents beginning
with dose 9 and increasing with selection dose. MCF-7TAX-
2 cells were 19.9-fold resistant to paclitaxel and 8.19-fold
cross-resistant to docetaxel at dose 9, increasing to 535-
fold and 72.6-fold resistance to paclitaxel and docetaxel,
respectively, at dose 12. Interestingly, cells selected for
resistance to docetaxel acquired cross resistance at dose 9
to paclitaxel (29.4-fold), which exceeded resistance to the
selection agent (15.9-fold). While resistance increased
with higher selection doses, the magnitude of cross-resist-
ance in MCF-7TXT cells to paclitaxel at dose 12 (251-fold)
was still greater than resistance to docetaxel (79.2-fold).
While anthracycline and taxane resistance generally
increased with increasing selection dose, the magnitude of
the resistance factor at each selection dose varied signifi-
cantly from experiment to experiment.
Relationship between Drug Resistance and Cellular 
Paclitaxel Uptake
Cells exposed to increasing concentrations of taxanes up
to dose 7 showed no significant differences in radiola-
belled paclitaxel accumulation compared to MCF-7CC
cells (data not shown). Similarly, as shown in Table 2,
when cells were selected to dose 8 drug levels, none of the
cells exhibited significant drug accumulation defects (p >
0.30 at 24 hours). Coincident with the onset of taxane
resistance at dose 9, paclitaxel uptake was markedly
reduced in the MCF-7TAX-2 and MCF-7TXT cell lines to 16%
and 30% of the uptake in MCF-7CC cells, respectively (p =
Significance Analysis of Microarrays (SAM) graphs depicting similarities and differences in gene expression between the MCF- 7DOX-2(A), MCF-7EPI (B), MCF-7TAX-2 (C), or MCF-7TXT (D) cell lines and their co-cultured parental (MCF-7CC) cell line Figure 1
Significance Analysis of Microarrays (SAM) graphs depicting similarities and differences in gene expression 
between the MCF-7DOX-2(A), MCF-7EPI (B), MCF-7TAX-2 (C), or MCF-7TXT (D) cell lines and their co-cultured 
parental (MCF-7CC) cell line. Genes not found to be different in expression from MCF-7CC cells are depicted in black, while 
upregulated and downregulated genes are depicted as red and green dots, respectively.B
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Table 2: Resistance factors and relative drug uptake for MCF-7 breast tumour cells selected for survival in increasing concentrations (doses) of chemotherapy drugs
ll Line Treatment Dose 8 Dose 9 Dose 10 Dose 11 Dose 12
Resistance 
Factor
Relative 
Uptake
Resistance 
Factor
Relative 
Uptake
Resistance 
Factor
Relative 
Uptake
Resistance 
Factor
Relative 
Uptake
Resistance 
Factor
Relative 
Uptake
MCF-7DOX-2 Doxorubicin 1.80 93% 2.48 46%* 3.59 37%** 42.5 37%** 27.8 33%***
Epirubicin 0.84 95% 2.91 38%** 6.99 29%*** 14.8 27%* 4.79 28%**
MCF-7EPI Doxorubicin 1.82 108% 39.2 17%*** 130.8 13%*** 391.6 13%*** 203.4 19%***
Epirubicin 1.05 114% 93.9 11%*** 422.6 9%*** 486.2 9%** 815.3 14%**
MCF-7TAX-2 Paclitaxel 1.00 115% 19.9 16%*** 119.2 10%*** 156.3 3%*** 535.2 2%***
Docetaxel 0.67 8.19 25.4 37.5 72.6
MCF-7TXT Paclitaxel 1.35 77% 29.4 30%*** 16.9 17%*** 148 28%** 251 9%***
Docetaxel 1.05 15.9 3.00 30.8 79.2
MCF-7 cells exhibiting progressive resistance to doxorubicin, epirubicin, paclitaxel, or docetaxel were obtained (MCF-7DOX-2, MCF-7EPI, MCF-7TAX-2, and MCF-7TXT cells, respectively). Drug 
sensitivity for each drug-resistant cell line and MCF-7CC cells at that selection dose was measured using a clonogenic assay. Resistance factors were then calculated by dividing the IC50 value for 
the drug-resistant cell lines by the IC50 value for MCF-7CC cells. Drug uptake into drug-resistant cell lines was also measured as described in Materials and Methods and expressed relative to 
uptake into MCF-7CC cells. Statistical analyses were conducted to determine if the drug uptake in the resistant cells varied significantly from MCF-7CC cells (* p < 0.05, ** p < 0.01 and *** p < 
0.001).BMC Cancer 2008, 8:318 http://www.biomedcentral.com/1471-2407/8/318
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3.93e-6 and 8.58e-5 respectively). In both taxane-resistant
cell lines, the uptake of paclitaxel continued to decrease,
such that by dose 12, MCF-7TAX-2 and MCF-7TXT cells took
up only 2% (p = 1.49e-5) and 9% (p = 3.17e-5) of the
uptake in MCF-7CC cells (Table 2). Despite these findings,
there did not appear to be a linear dose-dependent rela-
tionship between drug resistance and drug accumulation
(Figure 2C). While statistically significant reductions in
paclitaxel uptake did accompany the onset of paclitaxel
resistance, further increases in drug resistance occurred
with minimal changes in cellular paclitaxel uptake. This
suggested that paclitaxel resistance in MCF-7TAX-2  and
MCF-7TXT cells may not be solely related to changes in cel-
lular paclitaxel accumulation, particularly at higher selec-
tion doses.
Relationship between Drug Resistance and Cellular 
Doxorubicin and Epirubicin Uptake
The fluorescent nature of doxorubicin and epirubicin ena-
bled us to directly measure by flow cytometry changes in
cellular accumulation of these drugs during selection for
doxorubicin and epirubicin resistance. There was no dif-
ference in doxorubicin or epirubicin uptake between
drug-selected cells and MCF-7CC cells up to and including
dose 7 (data not shown) and dose 8 (Table 2). Similar to
the above paclitaxel uptake data, doxorubicin and epiru-
bicin uptake was significantly reduced in MCF-7DOX-2 cells
selected to dose 9, such that doxorubicin and epirubicin
uptake was only 46% (p = 0.02) and 38% (p = 0.003) of
uptake in MCF-7CC cells, respectively. The same trend was
seen for MCF-7EPI cells, although the amount of doxoru-
bicin and epirubicin uptake was significantly lower, repre-
senting 17% (p = 2.7e-5) and 11% (p = 6.21e-5) of the
uptake seen in MCF-7CC cells, respectively. Also similar to
our observations with the taxane-resistant cell lines, statis-
tically significant reductions in doxorubicin or epirubicin
uptake did accompany the onset of doxorubicin or epiru-
bicin resistance, respectively. However, further increases
in drug resistance were observed that did not appear to be
correlated with changes in drug accumulation (Figure 2A
and 2B). Again, this suggests that resistance to doxoru-
bicin or epirubicin may involve additional mechanisms
not related to drug uptake into cells.
Relationship between Drug Resistance, Drug 
Accumulation and Expression of Drug Transporters
The acquisition of drug resistance and/or changes in cellu-
lar drug accumulation observed above may be related to
changes in cellular expression of drug transporters known
to play a role in drug resistance. To assess this hypothesis,
we used quantitative reverse transcription PCR to accu-
rately measure the level of transcripts for the ABCB1,
ABCC1, ABCC2, ABCC4, ABCG2, and LRP drug transport-
ers. As shown in Figure 3A, acquisition of epirubicin
resistance at the threshold selection dose resulted in a dra-
matic induction of ABCB1 gene expression [X2(4) =
11.067, p < 0.05]. ABCB1 transcript levels were found to
increase further at higher selection doses. There also
appeared to be some elevation in ABCC2 transporter
expression in epirubicin resistance at higher selection
doses, but such changes in gene expression were found
not to be statistically significant ([X2(4) = 7.21, p > 0.05,
ns]; Figure 3C). Elevated ABCB1 expression was also
observed at the threshold dose (dose 9) in MCF-7TAX-2 and
MCF-7TXT, where resistance to paclitaxel and docetaxel
was first observed [X2(4) = 11.725, p < 0.05 and X2(4) =
10.495, p < 0.05, respectively]. The expression of ABCB1
increased further at higher selection doses, similar to our
observations in MCF-7EPI  cells (Figure 3A). ABCB1
appeared to be the only drug transporter which changed
expression upon selection for paclitaxel resistance,
whereas selection for docetaxel resistance also resulted in
increased ABCC2 transporter expression ([X2(4) = 10.038,
p < 0.05]; Figure 3C). Interestingly, selection for doxoru-
bicin resistance did not result in detectable increases in
ABCB1 expression (Figure 3A). A strong increase in
ABCC1 expression (Figure 3B) was observed for MCF-
7DOX-2 cells selected to dose 12 [X2(4) = 12.367, p < 0.05].
ABCG2 (Figure 3D), ABCC4 (data not shown) and LRP
(data not shown) transcript levels were unchanged during
selection for resistance to any of the anthracyclines or tax-
anes.
Cellular expression levels for the two most highly
expressed drug transporters were also assessed at the pro-
tein level through immunoprecipitation and immunob-
lotting experiments using antibodies specific for ABCB1
and ABCC1. The antibodies were used both for immuno-
precipitation of the drug transporters and for their quan-
tification in subsequent Western blotting experiments.
These experiments (Figure 4) demonstrated very clear evi-
dence of a dramatic increase in ABCB1 expression in the
MCF-7EPI, MCF-7TAX-2, and MCF-7TXT cell lines but not in
the MCF-7DOX-2cell line. Expression was clearly much
higher in MCF-7EPI cells than in MCF-7TAX-2 and MCF-7TXT
cells). Similar experiments with an ABCC1-specific anti-
body revealed that ABCC1 expression was induced in
MCF-7DOX-2 cells (selected to dose level 12), but not in any
of the other drug-resistant cell lines described in our
study. Our findings from immunoprecipitation/immuno-
blotting experiments are thus highly consistent with the
levels of ABCB1 and ABCC1 mRNAs determined from
quantitative PCR experiments (Figure 3).
Effect of Cyclosporin A on Paclitaxel, Doxorubicin, and 
Epirubicin Uptake into Cells
The above data strongly suggests that drug accumulation
defects accompany the acquisition of resistance to anthra-
cyclines and taxanes in MCF-7 cells and that this acquisi-
tion is temporally correlated with the increased expressionBMC Cancer 2008, 8:318 http://www.biomedcentral.com/1471-2407/8/318
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Relationship between drug uptake and drug resistance in various drug-resistant cell lines Figure 2
Relationship between drug uptake and drug resistance in various drug-resistant cell lines. Sensitivity of MCF-7TAX-
2, MCF-7TXT, MCF-7DOX-2, and MCF-7EPI cells (at various selection doses) to doxorubicin, epirubicin, or paclitaxel was meas-
ured using a clonogenic assay and compared to MCF-7CC cells to determine fold drug resistance (the resistance factor). Uptake 
of doxorubicin, epirubicin, and paclitaxel was also measured in the drug-resistant cell lines and expressed relative to uptake 
into MCF-7CC cells. The relationships between doxorubicin (A), epirubicin (B), or paclitaxel (C) uptake and fold resistance to 
various drugs in the cell lines were then plotted.BMC Cancer 2008, 8:318 http://www.biomedcentral.com/1471-2407/8/318
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of specific ABC transporters. However, as further drug
resistance was achieved above the threshold selection
dose, the degree of resistance did not highly correlate with
further reductions in drug accumulation, suggesting that
drug resistance may involve additional mechanisms. To
address these issues, cells were pre-treated with the pan
ABC drug transporter inhibitor cyclosporin A, after which
drug accumulation into cells was monitored. As shown in
Figure 5A, when MCF-7DOX-2 and MCF-7EPI cells (selected
to dose 9) were treated with the ABC inhibitor, doxoru-
bicin uptake into MCF-7DOX-2 cells was restored to levels
seen in co-cultured MCF-7 cells. Doxorubicin uptake into
MCF-7EPI cells was partially restored from 12 to 60% of
uptake into MCF-7CC cells. Nevertheless, even in the pres-
ence of cyclosporin A, statistically significant differences
in drug accumulation between the two cell lines were
observed (p = 0.03). When cells selected to dose 12 were
examined for doxorubicin uptake in the absence or pres-
ence of cyclosporin A, MCF-7DOX-2  and MCF-7EPI cells
exhibited only a partial restoration of drug accumulation
(from 26 to 58% and from 14 to 20% of uptake into MCF-
7CC cells, respectively). Statistically significant differences
in drug accumulation between MCF-7DOX-2 cells or MCF-
7EPI cells and MCF-7CC cells were again evident in the pres-
ence of cyclosporin A (p values of 0.01 and 0.003, respec-
tively).
Levels of drug transporters at various selection doses in cells selected for progressive resistance to paclitaxel, docetaxel, dox- orubicin, and epirubicin (MCF-7TAX-2, MCF-7TXT, MCF-7DOX-2, and MCF-7EPI cells, respectively) Figure 3
Levels of drug transporters at various selection doses in cells selected for progressive resistance to paclitaxel, 
docetaxel, doxorubicin, and epirubicin (MCF-7TAX-2, MCF-7TXT, MCF-7DOX-2, and MCF-7EPI cells, respectively). 
MCF-7TAX-2, MCF-7TXT, MCF-7DOX-2, and MCF-7EPI cells are represented by black, white, grey, and grey striped bars, respec-
tively. The symbol * denotes changes in gene expression that vary significantly from levels in cells selected to dose 8 (p < 0.05).BMC Cancer 2008, 8:318 http://www.biomedcentral.com/1471-2407/8/318
Page 10 of 16
(page number not for citation purposes)
Treatment of MCF-7TAX-2 and MCF-7TXT cells (selected to
dose 9) with 5 μM cyclosporin A also caused a partial res-
toration of paclitaxel uptake in these cells (from 14 to
63% and from 34 to 64% of uptake in MCF-7CC cells,
respectively). However, paclitaxel uptake into MCF-7TAX-2
cells was still found to be statistically significant from co-
cultured MCF-7 cells in the presence of this agent (p =
0.006). Interestingly, when MCF-7TAX-2 and MCF-7TXT cells
selected to dose 12 were treated with cyclosporin A, a
complete restoration of paclitaxel uptake was observed,
such that there were no differences in paclitaxel uptake
between MCF-7TXT or MCF-7TAX-2 cells and MCF-7CC cells
(p values of 0.12 and 0.23, respectively).
Effect of Cyclosporin A on Cellular Sensitivity to Paclitaxel 
and Doxorubicin
While the addition of 5 μM cyclosporin A completely or
partially restored uptake of doxorubicin into MCF-7DOX-2
cells selected to dose 9 and dose 12, respectively, this
treatment exhibited little to no change in the sensitivity of
cells to doxorubicin at either selection dose (Figure 4B).
Treatment with cyclosporin A induced a minor 2- and 4-
fold decrease in the IC50 for doxorubicin in MCF-7EPI cells
selected to dose 9 and 12, respectively, suggesting a small,
partial restoration of drug sensitivity. This was despite the
ability of cyclosporin A to induce a 6-fold increase in dox-
orubicin uptake into MCF-7EPI cells selected to dose 9 and
virtually no change in drug uptake into MCF-7EPI cells
selected to dose 12 (Figure 4A). This suggests a clear dis-
cordance between the degree of drug resistance and the
degree of drug accumulation into these drug-resistant
cells. Underscoring this view, cyclosporin A induced full
restoration of paclitaxel uptake into MCF-7TAX-2  cells
selected to dose 12 but had little effect on cellular sensitiv-
ity to paclitaxel. MCF-7TXT cells selected to dose 12 also
showed a full restoration of paclitaxel uptake in response
to cyclosporin A and a substantial (8-fold) but incomplete
restoration in sensitivity to paclitaxel. In MCF-7TXT cells
selected to dose 9, the significant restoration in paclitaxel
uptake by cyclosporin A did not result in any change in
resistance to paclitaxel.
Levels of expression of the ABCB1 and ABCC1 drug transporters in MCF-7CC, MCF-7DOX-2, MCF-7EPI, MCF-7TAX-2 and MCF- 7TXT cell lines at selection dose 12 Figure 4
Levels of expression of the ABCB1 and ABCC1 drug transporters in MCF-7CC, MCF-7DOX-2, MCF-7EPI, MCF-
7TAX-2 and MCF-7TXT cell lines at selection dose 12. The ABCB1 and ABCC1 drug transporters were immunoprecipi-
tated from whole cell extracts using protein A/G sepharose and antibodies specific for ABCB1 (A) or ABCC1 (B). The level of 
expression of the drug transporters was then assessed in immunoblotting experiments using the same antibodies.BMC Cancer 2008, 8:318 http://www.biomedcentral.com/1471-2407/8/318
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Effects of cyclosporin A on drug uptake and drug sensitivity in co-cultured control and drug-resistant cells Figure 5
Effects of cyclosporin A on drug uptake and drug sensitivity in co-cultured control and drug-resistant cells. 
Cells selected to dose 9 or dose 12 levels of doxorubicin, epirubicin, paclitaxel, or docetaxel were pre-treated with or without 
5 μM cyclosporin A and monitored for uptake of paclitaxel or doxorubicin relative to MCF-7CC cells (panel A). Identical cells 
pre-treated with or without 5 μM cyclosporin A were also assessed for their sensitivity to doxorubicin or paclitaxel using a 
clonogenic assay (panel B).BMC Cancer 2008, 8:318 http://www.biomedcentral.com/1471-2407/8/318
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Discussion
A Threshold for Acquisition of In Vitro Taxane and 
Anthracycline Resistance at Clinically Relevant 
Concentrations
As described above, a number of proteins have been
implicated in the ability of tumour cells to acquire resist-
ance to chemotherapy agents. Drug transporters are
highly expressed in a variety of drug-resistant cell lines,
but it is unclear whether their enhanced expression is tem-
porally or causally correlated with the acquisition of drug
resistance. Even if there is a temporal relationship
between transporter expression and the induction of drug
resistance, it is also not known whether additional mech-
anisms are temporally correlated with the acquisition of
drug resistance and/or whether drug transporters/cellular
drug accumulation defects represent the predominant
mechanism for drug resistance. It is also unknown
whether acquisition of in vitro drug resistance takes place
at clinically relevant doses. To our knowledge, this is the
first study to address these issues. The data presented in
this study (Table 2) strongly suggests that in selection for
resistance to four different chemotherapy drugs, a specific
threshold concentration of drug is required for drug resist-
ance to be achieved. This threshold equates to "dose 9" or
3.7 nM paclitaxel, 3.3 nM docetaxel, 29 nM doxorubicin,
and 31.5 nM epirubicin. At dose 9, cells acquire resistance
not only to their selection agent, but also cross-resistance
to an agent of similar drug class (Table 2), and in some
instances to drugs of other classes (data not shown). The
threshold concentration required for selection of drug
resistance appears to be approximately 2-fold above the
IC50 value for the selection agent in wild-type cells. Inter-
estingly, this concentration is also significantly lower than
that observed in the plasma of cancer patients treated with
these agents [39-42], suggesting that selection for drug-
resistant variants may also take place at drug doses admin-
istered to patients.
Dose-specific Induction of Various Drug Transporters At or 
Above the Threshold Concentration Required for the 
Acquisition of Drug Resistance
To our knowledge, this is the first study to profile changes
in the expression of drug transporters as cells acquire
resistance during selection for survival in increasing con-
centrations of anthracyclines and taxanes. Through these
experiments, we were able to verify that the onset of
anthracycline or taxane resistance in breast tumour cells
is, in some but not all instances, temporally correlated
with changes in the expression of specific drug transport-
ers (Figures 3 and 4). The transporters changing expres-
sion upon acquisition of drug resistance appear to be
dependent upon the selection agent. For example, selec-
tion for resistance to paclitaxel and epirubicin resulted in
a dose-dependent increase in the expression of the ABCB1
drug transporter (P-glycoprotein), without a significant
change in the expression of any other drug transporter. In
contrast, acquisition of resistance to docetaxel correlated
with the induction of both the ABCB1 and ABCC2 trans-
porters at dose 9. ABCB1 expression continued to increase
with increasing selection dose, while ABCC2 expression
fell in a dose-dependent manner after induction at dose 9.
During selection with doxorubicin, the onset of doxoru-
bicin resistance was not accompanied by any change in
the expression of drug transporters associated with drug
resistance. Only at the highest selection dose (dose 12)
was the expression of a drug transporter induced, namely
ABCC1. It appears that some other protein or mechanism
was responsible for the doxorubicin accumulation defect
and doxorubicin resistance observed at lower selection
doses. Taken together, the data suggests that drug resist-
ance may stem in some instances, from the combined
expression of a variety of drug transporters and that the
expression of drug transporters can vary with selection
dose. The data also suggests that doxorubicin resistance
and doxorubicin accumulation defects can occur in cells
without changes in the expression of any of the known
drug transporters.
Lack of Relationship Between Drug Uptake and Drug 
Resistance at Low and High Selection Doses
Data from this study also illustrates an additional interest-
ing trend. While the onset of drug resistance could be tem-
porally correlated with reductions in drug accumulation
and in some instances, changes in the expression of drug
transporters, there appeared to be little correlation
between the magnitude of drug resistance and reductions
in drug uptake at higher selection doses (Figure 2). This
suggests that additional mechanisms must be involved in
the acquisition of drug resistance, particularly at higher
drug concentrations. It is also possible that even at the
threshold selection dose additional mechanisms unre-
lated to drug transporters may play a role in the observed
drug resistance and drug accumulation defects. To help
address these issues, we employed the use of the pan drug
transporter inhibitor cyclosporin A. Although one study
claimed cyclosporin A was not an effective inhibitor or
substrate of the ABCG2 transporter [43], another showed
that cyclosporin A could effectively inhibit the activity of
the ABCB1, ABCC1, ABCG2 and LRP [44] drug transport-
ers. Upon addition of cyclosporin A to MCF-7DOX-2, MCF-
7TAX-2, MCF-7EPI, and MCF-7TXT cells selected to dose 9 or
dose 12, there were significant reversals in both doxoru-
bicin and paclitaxel accumulation defects in the cell lines
(Figure 5A). At dose 9, all of the cell lines exhibited signif-
icant restorations in either doxorubicin or paclitaxel
uptake, particularly for doxorubicin uptake into MCF-
7DOX-2 cells. For cells selected to dose 12, significant resto-
ration of doxorubicin accumulation was noted in MCF-
7DOX-2  cells, and a complete restoration of paclitaxel
uptake was observed in MCF-7TAX-2 and MCF-7TXT cells.BMC Cancer 2008, 8:318 http://www.biomedcentral.com/1471-2407/8/318
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Yet, many of these restorations in drug uptake were not
accompanied by equivalent restorations in drug sensitiv-
ity (Figure 5B). This was particularly evident for doxoru-
bicin uptake into MCF-7DOX-2 cells selected to dose 12 and
for paclitaxel uptake into MCF-7TAX-2 cells selected to dose
12. These findings strongly suggest that resistance to dox-
orubicin and to paclitaxel cannot be attributed solely to
the expression of drug transporters and/or reductions in
cellular drug accumulation. Moreover, the cyclosporin A
experiments further suggest that additional drug resist-
ance mechanisms must be present in our panel of drug-
resistant cell lines. Some likely additional mechanisms are
described below.
While we have reported that 5 μM cyclosporin A cannot
completely restore drug uptake into the drug-resistant cell
lines used in this study, this appears to be in contrast to
several previously published studies using cyclosporin A
at concentrations ranging from 0.5 to 10 μM [16,43,45-
47]. One possible explanation for this could be that the
number and degree of expression of drug transporters
may be higher in some cell lines employed in this study,
particularly at higher selection doses. The mechanisms
responsible for the drug accumulation defects may also
differ amongst cell lines. While it is also possible that
complete restoration of drug sensitivity could have been
obtained at higher cyclosporin A concentrations, it is
important to note that in both MCF-7TAX-2, and MCF-7TXT
cells (at selections doses 9 and 12), full restoration of drug
uptake was observed. It is acknowledged, however, that
cyclosporin A concentrations may have been insufficient
to completely restore drug uptake into MCF-7DOX-2, MCF-
7EPI cells.
As for the effects of more specific drug transporter inhibi-
tors, we have observed that the ABCB1-specific inhibitor
valspodar could restore sensitivity to paclitaxel but not
doxorubicin in similarly selected MCF-7TAX cells. Moreo-
ver, valspodar was unable to restore sensitivity to doxoru-
bicin or paclitaxel in previously selected MCF-7DOX cells,
which strongly express the ABCB1 drug transporter.
Higher concentrations of valspodar had no further effect
on drug sensitivity [35]. These observations suggest that
inhibitors with strong affinity and specificity for ABCB1
cannot fully restore sensitivity to paclitaxel- or doxoru-
bicin-resistant breast tumour cells. Valspodar treatment
also had no effect on the localization of epirubicin in
MCF-7EPI cells. While epirubicin is localized to the nucleus
in wildtype MCF-7 cells, the drug is found in lysosomes of
MCF-7EPI cells, suggesting that it cannot associate with its
target (DNA) within the nucleus (Eng et al., manuscript in
preparation). The inability of valspodar to restore drug
localization to the nucleus provides further evidence that
other proteins play a role in acquired resistance to anthra-
cyclines and taxanes in breast tumour cells.
It is possible that ABCB1 gene silencing (siRNA)
approaches would be more successful than cyclosporin A
or valspodar in restoring drug sensitivity to drug-resistant
cell lines. However, since cDNA microarray studies sug-
gest that multiple proteins play a role in acquired drug
resistance, it would be unexpected that ABCB1 siRNAs
could fully restore drug sensitivity in our drug-resistant
breast tumour cell lines. Recent studies also suggest that
ABCB1 RNA interference approaches have mixed success
in restoring drug sensitivity to drug-resistant cell lines.
While ABCB1 siRNAs were able to restore drug sensitivity
in daunorubicin-resistant gastric, hepatic, and pancreatic
tumour cell lines [48,49], they showed little ability to
restore drug sensitivity in paclitaxel-resistant PC-3-TxR
prostate cancer cells [50]. The above findings thus support
the hypothesis that multiple mechanisms may be
involved in the acquisition of drug resistance in tumour
cells.
Additional Mechanisms of Drug Resistance At or Above the 
Threshold Selection Dose
What additional mechanisms could be involved at the
onset or at high levels of drug resistance? cDNA microar-
ray analysis was used recently by our research group to
identify changes in gene expression that take place during
selection for resistance to specific taxanes or anthracy-
clines. Interestingly, in addition to the drug transporters,
a number of additional genes changed expression at or
above the threshold selection dose. One such gene (a
"1C" aldoketoreductase) increased its expression in MCF-
7DOX-2 cells by almost 35-fold from dose 8 to dose 12
(Veitch et al., manuscript in submission). Moreover, addi-
tion of a specific pharmacological inhibitor of aldoketore-
ductase 1C2 (5-β cholanic acid) almost completely
restored sensitivity to doxorubicin in MCF-7DOX-2 cells at
dose 12 (Veitch et al., manuscript in submission). This
strongly suggests a role for aldoketoreductases in anthra-
cycline resistance, which may involve their ability to cov-
ert anthracyclines to less-toxic 13-hydroxy metabolites
and/or block anthracycline-mediated DNA damage
[51,52]. Assessment of the subcellular location of anthra-
cyclines in MCF-7DOX-2 and MCF-7EPI cells by fluorescence
microscopy further revealed that anthracycline resistance
at or above the threshold selection dose could be tempo-
rally correlated with exclusion of anthracyclines from the
nucleus and their localization to lysosomal vesicles for
possible exocytosis from cells (Eng et al., manuscript in
preparation). This nuclear exclusion of anthracyclines in
anthracycline-resistant cells above threshold could not be
restored by the addition of cyclosporin A or valspodar at
concentrations able to restore drug uptake into these cells.
Thus, mechanisms unrelated to cellular drug accumula-
tion appear to be temporally and/or causally related to the
acquisition of drug resistance in MCF-7 cells.BMC Cancer 2008, 8:318 http://www.biomedcentral.com/1471-2407/8/318
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Conclusion
In conclusion, this study provides an assessment of the
temporal and causal relationship between the expression
and activity of drug transporters in MCF-7 cells and the
acquisition of resistance to anthracyclines and taxanes.
Our data strongly suggests that while reduced drug accu-
mulation and the induction of expression of various drug
transporters is temporally correlated with the onset of
drug resistance in MCF-7 breast tumour cells at clinically
relevant drug concentrations, the magnitude of resistance
appears to be poorly correlated with the degree of reduc-
tion in cellular drug accumulation, particularly at higher
selection doses. In addition, resistance is not substantially
reduced upon restoration of drug accumulation into cells,
suggesting the presence of additional drug resistance
mechanisms, two of which (for doxorubicin) likely
involve the action of aldoketoreductases and changes in
cellular drug localization. Future studies involving these
cell lines should also help assess the temporal correlation
between the acquisition of drug resistance and specific
chromosomal amplifications or epigenetic changes impli-
cated in the induced expression of drug resistance-related
proteins. This increased knowledge of the relevance of var-
ious mechanisms to drug resistance in vitro should help
identify better strategies for possible circumvention of
drug resistance in cancer patients.
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